Crotti Lia, Kotta Maria-Christina
IRCCS Istituto Auxologico Italiano, Center for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Milan, Italy; Department of Molecular Medicine, University of Pavia, Italy; Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital IRCCS Istituto Auxologico Italiano, Milan, Italy.
IRCCS Istituto Auxologico Italiano, Center for Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular Genetics, Milan, Italy; Department of Molecular Medicine, University of Pavia, Italy.
Int J Cardiol. 2017 Jun 15;237:45-48. doi: 10.1016/j.ijcard.2017.03.119.
Sudden cardiac death (SCD) has a strong familial component; however, our understanding of its genetic basis varies significantly according to the underlying causes. When coronary artery disease is involved, the predisposing genetic background is complex and despite some interesting findings it remains largely unknown. Quite different is the case of monogenic structural and non-structural heart diseases, in which a number of disease-causing genes have been established and are being used in clinical practice. As SCD can be the first clinical manifestation of inherited syndromes, in order to ascertain the cause of death, it is extremely important to include molecular autopsy among the standard post-mortem examinations. Indeed, molecular screening of the major disease-causing genes in the deceased person is often the only way to achieve a post-mortem diagnosis in channelopathies, which may prove crucial for the identification and management of at risk family members. Overall, these data, together with the inclusion in current guidelines of molecular screening for diagnosis and/or risk stratification of specific inherited cardiac diseases, exemplify how research on the genetic basis of SCD may be deeply translational, while the transition of genetic testing from the research to the diagnostic setting is already improving every-day clinical practice.
心源性猝死(SCD)具有很强的家族性因素;然而,我们对其遗传基础的理解因潜在病因的不同而有很大差异。当涉及冠状动脉疾病时,易患遗传背景较为复杂,尽管有一些有趣的发现,但在很大程度上仍不清楚。单基因结构性和非结构性心脏病的情况则大不相同,在这些疾病中,已经确定了许多致病基因并应用于临床实践。由于SCD可能是遗传性综合征的首发临床表现,为了确定死因,在标准尸检中纳入分子尸检极为重要。事实上,对死者主要致病基因进行分子筛查往往是在通道病中实现死后诊断的唯一途径,这对于识别和管理高危家庭成员可能至关重要。总体而言,这些数据,以及当前指南中纳入针对特定遗传性心脏病的分子筛查以进行诊断和/或风险分层,例证了SCD遗传基础研究如何具有深刻的转化意义,而基因检测从研究到诊断环境的转变已经在改善日常临床实践。